Melinta Therapeutics initiated at Jefferies

Melinta Therapeutics initiated with a Buy at Jefferies. Jefferies analyst David Hoang started Melinta Therapeutics with a Buy rating and $15 price target. The analyst is a differentiated pure play in antibiotics as it has four marketed products and a fully trained, recently expanded sales force, Hoang tells investors in a research note. He believes Melinta has the scale to achieve commercial success in a “challenging” therapeutic space.
https://thefly.com/landingPageNews.php?id=2788311